Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
HCC1428 Ceritinib
0.031623
ALK
RTK
 1.0431 0.00026
HCC1428 Ceritinib
0.1
ALK
RTK
 1.0446 -0.00011
HCC1428 Ceritinib
0.31623
ALK
RTK
 0.9156 0.00008
HCC1428 Ceritinib
1.0
ALK
RTK
 0.5891 0.01222
HCC1428 Ceritinib
3.1623
ALK
RTK
 -0.1653 0.32425
HCC1428 Ceritinib
10.0
ALK
RTK
 -0.8673 0.83636
HCC1428 Neratinib
0.00031623
EGFR/HER2
RTK
 1.0230 0.00648
HCC1428 Neratinib
0.001
EGFR/HER2
RTK
 1.0216 0.00575
HCC1428 Neratinib
0.0031623
EGFR/HER2
RTK
 0.9844 0.00319
HCC1428 Neratinib
0.01
EGFR/HER2
RTK
 1.0424 -0.00293
HCC1428 Neratinib
0.031623
EGFR/HER2
RTK
 1.0741 0.00037
HCC1428 Neratinib
0.1
EGFR/HER2
RTK
 0.9587 0.00010
HCC1428 Neratinib
0.31623
EGFR/HER2
RTK
 0.9415 -0.00078
HCC1428 Neratinib
1.0
EGFR/HER2
RTK
 0.6768 0.02380
HCC1428 Neratinib
3.1623
EGFR/HER2
RTK
 -0.0412 0.21839
HCC1428 Tivantinib
0.001
MET
RTK
 1.0024 0.00396
HCC1428 Tivantinib
0.0031623
MET
RTK
 1.1007 -0.00420
HCC1428 Tivantinib
0.01
MET
RTK
 1.1688 -0.00135
HCC1428 Tivantinib
0.031623
MET
RTK
 0.9895 0.00336
HCC1428 Tivantinib
0.1
MET
RTK
 0.8879 0.03182
HCC1428 Tivantinib
0.31623
MET
RTK
 0.3758 0.20520
HCC1428 Tivantinib
1.0
MET
RTK
 0.1317 0.33990
HCC1428 Tivantinib
3.1623
MET
RTK
 0.0657 0.24459
HCC1428 Tivantinib
10.0
MET
RTK
 0.0341 0.17241
HCC1428 Cediranib
0.001
VEGFR/cKIT
RTK
 1.1400 -0.00495